MyMD Pharmaceuticals (MyMD Pharmaceuticals) Marketable Securities : $1.51 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is MyMD Pharmaceuticals Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. MyMD Pharmaceuticals's Marketable Securities for the quarter that ended in Mar. 2024 was $1.51 Mil.

MyMD Pharmaceuticals's annual Marketable Securities declined from Dec. 2021 ($11.00 Mil) to Dec. 2022 ($4.09 Mil) and declined from Dec. 2022 ($4.09 Mil) to Dec. 2023 ($2.24 Mil).

MyMD Pharmaceuticals Marketable Securities Historical Data

The historical data trend for MyMD Pharmaceuticals's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MyMD Pharmaceuticals Marketable Securities Chart

MyMD Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Marketable Securities

11.00

4.09

2.24

MyMD Pharmaceuticals Quarterly Data
	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Marketable Securities	Get a 7-Day Free Trial											15.36	11.53	8.17	2.24	1.51

MyMD Pharmaceuticals Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

MyMD Pharmaceuticals (NAS:MYMD) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

MyMD Pharmaceuticals Marketable Securities Related Terms

Thank you for viewing the detailed overview of MyMD Pharmaceuticals's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

MyMD Pharmaceuticals (MyMD Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MyMD Pharmaceuticals Inc (NAS:MYMD) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

DQS:Germany DQS:Germany

Address

855 North Wolfe Street, Suite 601, Baltimore, MD, USA, 21205

Website

https://www.mymd.com

MyMD Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. It is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-1R is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and a monoamine oxidase enzyme type B.

Executives

Paul Rivard	officer: EVP of Operations, GC	C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Joshua Silverman	director	IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Caroline C Williams	10 percent owner	324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
Adam Kaplin	officer: Chief Scientific Officer	C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Jude Uzonwanne	director	C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Craig Eagle	director	POST OFFICE BOX 4590, NEW YORK NY 10163
Chapman Christopher C Jr	director, officer: President, Chief Med. Officer	C/O STAR SCIENTIFIC, INC., 7475 WISCONSIN AVENUE, SUITE 850, BETHESDA MD 20814
Ian Rhodes	officer: Interim CFO	1375 KINGS HIGHWAY EAST, FAIRFIELD CT 06824
Stuart M Benson	officer: Chief Financial Officer	EMPIRE STATE BUILDING, 350 5TH AVE., SUITE 7520, NEW YORK NY 10118
Hudson Bay Capital Management Lp	10 percent owner	28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Sander Gerber	10 percent owner	C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Robert C Schroeder	director	37 MAIN STREET, COLD SPRING HARBOR, NEW YORK NY 11724
Howard Yeaton	officer: CEO, CFO	79 LLOYD ROAD, HOHOKUS NJ 07423
Tarbox Richard C Iii	director	AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086
Christopher C Schreiber	director	AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086